| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192608 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(10 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(10 years from now) | |
| US9072781 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(10 years from now) | |
Morphine Sulfate is owned by Fresenius Kabi Usa.
Morphine Sulfate contains Morphine Sulfate.
Morphine Sulfate has a total of 3 drug patents out of which 0 drug patents have expired.
Morphine Sulfate was authorised for market use on 30 October, 2013.
Morphine Sulfate is available in solution;intramuscular, intravenous dosage forms.
Morphine Sulfate can be used as management of chronic pain in patients requiring opioid analgesia; treatment of pain.
The generics of Morphine Sulfate are possible to be released after 12 March, 2034.
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 30 October, 2013
Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MORPHINE SULFATE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic